SNF472
Published
Unassigned
New Medicines
Calcific uraemic arteriolopathy (CUA) in ESRD
Information
New molecular entity
Sanifit
Sanifit
Development and Regulatory status
Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Category
IV formulation of myo-inositol hexaphosphate, which selectively inhibits formation & growth of hydroxyapatite crystals. SNF 472 blocks the final pathway of calcification, inhibiting formation and growth of calcium phosphate micro-crystals in soft tissues.
An uncommon condition, affecting 1-4% of the population with end-stage renal failure [3]. CUA in ESRD is a severe form of vascular calcification characterised by painful necrotic skin ulcers and very high mortality. No approved agents are available for therapeutic use (as of mid-2019) [6].
Calcific uraemic arteriolopathy (CUA) in ESRD
Intravenous